Monthly Archives: April 2020

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Velocity Financial, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 30, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Velocity Financial, Inc. ("Velocity" or "the Company") (NYSE:VEL) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Velocity commenced its initial public offering ("IPO") on January 17, 2020, offering 7,250,000 shares for $13.00 per share. The Company's share price has sharply declined since the IPO, falling as low as $2.47 per share, an 81% drop from the IPO price.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 587779

SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Phoenix Tree Holdings Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 30, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Phoenix Tree Holdings Limited ("Phoenix Tree" or "the Company") (NYSE:DNK) for violations of the federal securities laws.

Investors who purchased the Company's American Depositary Shares ("ADSs") pursuant and/or traceable to prospectuses and registration statements issued in connection with the Company's January 22, 2020 initial public offering ("IPO"), are encouraged to contact the firm before June 26, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Phoenix Tree misrepresented the number and nature of renter complaints before its IPO. The Company also misrepresented its exposure to adverse effects on the rental market in China due to the Wuhan coronavirus. Following its IPO, reports exposed that Phoenix Tree experienced significant financial problems based on the coronavirus outbreak. Based on these facts, the Company's public statements and Registration Statements were false and materially misleading. When the market learned the truth about Phoenix Tree, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 587778

PHOENIX TREE INVESTOR ALERT: Shareholder Class Action Lawsuit Filed

BOSTON, MA / ACCESSWIRE / April 30, 2020 / Thornton Law Firm LLP announces a securities class action lawsuit has been filed on behalf of shareholders of Phoenix Tree Holdings Limited (NYSE:DNK). Investors who purchased DNK securities in connection with the IPO on January 22, 2020, are encouraged to visit https://www.tenlaw.com/cases/DNK. Investors may also contact Thornton Law Firm at shareholder@tenlaw.com, or call 617-531-3917. Investors outside the USA, including derivative investors, are encouraged to contact Thornton Law Firm to discuss their potential recovery rights.

FOR MORE INFORMATION, VISIT: https://www.tenlaw.com/cases/DNK

Interested DNK shareholders have until June 26, 2020 to apply to be a lead plaintiff. The lawsuit alleges violations of the federal securities laws, and the class has not yet been certified. Until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. There is no minimum number of shares required to be a class member.

Phoenix Tree Holdings Limited is a Cayman Islands holding company that leases and manages apartments in China, which it rents to tenants under the Danke Apartment and Dream Apartment brands. It is alleged that at the time of its IPO, Phoenix generated revenue primarily from rents and service fees and that as of September 30, 2019, it operated in 13 cities in China, including Wuhan, where a portion of its 5,000-plus employees worked.

The complaint alleges that the Offering Materials connected to the company's IPO omitted the following facts: (1) Phoenix received complaints and negative press concerning its questionable business conduct before the IPO, including its misleading practice of deceptively persuading renters to procure loans whose proceeds financed the Company's business and operations; (2) that competition in the residential rental market in China dropped significantly at the time of the IPO, especially in Wuhan, the epicenter of the Coronavirus pandemic, as the Coronavirus spread throughout the very locations where Phoenix operated; (3) that Phoenix's technological capabilities could not enable the Company to surmount the complications and erosion of business due to the spread of the Coronavirus throughout China at the time of the IPO; (4) that Phoenix was competing with extremely adverse developments in China at the time of the IPO due to the Coronavirus that presented events, risks and uncertainties that were reasonably likely to materially affect Phoenix's business, operations and financial condition, including a material increase in renter complaints and negative press and the prospect that renters could not continue to pay rent and service fees under conditions then existing as of the IPO; (5) consequently, Phoenix was positioned no differently than its competitors in managing the fallout from customer complaints or adverse implications stemming from the coronavirus in China and (6) as a result, Phoenix's public statements were materially false and misleading at all relevant times.

If you are an investor that suffered losses in DNK, and wish to participate, learn more, or discuss the issues surrounding the lawsuit, please contact the Thornton Law Firm's shareholder rights team at http://www.tenlaw.com/cases/DNK, by email at shareholder@tenlaw.com, or calling 617-531-3917.

FOR MORE INFORMATION: https://www.tenlaw.com/cases/DNK

Thornton Law Firm's securities attorneys are highly experienced in representing individual shareholders and institutional investors in recovering damages caused by violations of the securities laws. Its attorneys have established track records litigating securities cases in courts throughout the country and recovering losses on behalf of shareholders. This may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

CONTACT:

Thornton Law Firm LLP
State Street Financial Center
1 Lincoln Street
Boston, MA 02111
www.tenlaw.com/cases/DNK

SOURCE: Thornton Law Firm LLP

ReleaseID: 587781

Imperalis Holding Corp. (IMHC) Provides Company Update and Announces Removal of “Yield Sign” From OTC

SHERIDAN, WY / ACCESSWIRE / April 30, 2020 / Imperalis Holding Corp. (OTC PINK:IMHC), a premium cannabinoid wellness company, announced today that it now meets OTC Markets Groups Guidelines for Providing Adequate Current Information. The Company has submitted all necessary documentation to qualify as a "Pink Current" company on the OTC Markets and therefore will no longer have a "Yield Sign" on its stock.

The Company is also pleased to announce that it has been approved for an Amazon seller's account and is working now to provide UPC codes to the retailer so that it can start selling its hemp-derived, non-psychoactive CBD oils on the platform. The company's hemp-derived CBD products use only the purest natural oils and ingredients. They do not contain Parabens, Formaldehyde, Oxybenzones, DEA/TEA/MEA (Ethanolamines), Sodium Lauryl or Laureth Sulfates, or Artificial Perfumes.

It was last year that Amazon surpassed Walmart as the biggest retailer on the planet and the platform offers a tremendous market for Imperalis to capitalize on. The company intends to provide more information on when products will launch with the retailer in upcoming weeks.

About Imperalis Holding Corp.

Imperalis Holding Corp. (the "Company") is a cannabinoid and wellness company. The company believes that everyone has the right to pure, natural skin and hair care products; free of harsh chemicals and preservatives. Products are crafted by hand, using only natural ingredients like coconut oil, hemp oil, black seed oil, shea butter, and cocoa butter. Considering that the average person uses 6-12 products with over 168 different chemicals in them every morning, the company has made it their mission to provide you with alternative products to help you cut down on the amounts of potentially harmful substances entering your body on a daily basis. For more information, please visit our website: https://cannacuresciences.com/ If you and your family are looking to cut down on your exposure to endocrine disrupting chemicals and are interested in exploring our line of natural skin and hair care products, please visit our online store at http://www.cannacuresciences.com.

Cautionary Note Regarding Forward-Looking Statements

FORWARD-LOOKING STATEMENTS:

This press release may contain certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers are cautioned that all forward-looking statements contained herein are reasonable, any assumption could be inaccurate and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

Contact:

Investor Relations
888-662-8444
info@cannacuresciences.com

SOURCE: Imperalis Holding Corp.

ReleaseID: 587580

Julie L. Stackhouse Joins Neocova Board of Directors

Appointed to AI, Data Analytics and Core Banking-focused Fintech After Career with Federal Reserve

ST. LOUIS, MO / ACCESSWIRE / April 30, 2020 / Neocova, the St. Louis-based technology provider with a platform built specifically for community banks and credit unions, has today appointed Julie L. Stackhouse to its board of directors.

Stackhouse retired in February 2020 after 32 years in bank supervision with the Federal Reserve, most recently as Executive Vice President and Managing Officer of the Banking Supervision, Credit Risk Management, Community Development and Learning Innovation Division of the Federal Reserve Bank of St. Louis. Her distinguished career includes positions as the Vice President of the Risk Management Department of the Federal Reserve Bank of Minneapolis and Senior Vice President with the Federal Reserve Bank of Kansas City.

"Julie brings a wealth of banking and regulatory knowledge to our board of directors, and we are excited to welcome her to the Neocova team," said Sultan Meghji, CEO and Co-Founder of Neocova. "We believe her strong background in financial services regulation, especially in credit risk as well as banking crises in agriculture, real estate and the financial markets, will be extremely valuable as Neocova continues to grow and establish meaningful relationships with community financial institutions and their regulators."

In addition to Stackhouse and Meghji, Neocova's board of directors includes Bob Flores, President & CEO of Applicology Inc. and former Chief Technology Officer with the Central Intelligence Agency, and Stephen Glassgold, a managing director in the financial services group at Piper Sandler.

About Neocova

Neocova is a financial technology firm headquartered in St. Louis with operations in New York. Neocova offers artificial intelligence, analytics and other cloud-based systems that enable financial institutions to operate more efficiently, effectively and securely by removing the stresses of managing complex systems and complicated contracts. More information is available at https://neocova.com/

Media Contact:

Michelle Mead
Caliber Corporate Advisers
888.550.6385 ext.7
michelle@calibercorporate.com

SOURCE: Neocova

ReleaseID: 587773

1000th COVID-19 clinical trial posted today, a milestone signaling the continued exponential growth in research efforts against Coronavirus

A symbolic milestone was passed today when the 1000th new clinical trial for COVID-19 was listed, as reported by Ancora.ai. Clinical trials represent the safest and most effective way to generate scientific evidence on prospective testing, treatment and prevention strategies to combat Coronavirus.

Zurich, Switzerland – April 30, 2020 /MarketersMedia/

A symbolic milestone was passed today when the 1000th clinical trial for COVID-19 was listed on clinicaltrials.gov, the global public database for clinical trial registry. Clinical trials to study Coronavirus strategies quickly began to be initiated in January 2020 and have been increasing exponentially in number since.

Ancora.ai, a new digital health product for clinical trial search and match, has tracked a 433% increase in the number of clinical trials listed for COVID-10 in the past month alone. These trials need to recruit more than 430,000 participants to be fully enrolled and completed.

Healthcare systems are overwhelmed due to the pandemic and have little spare time or resource to devote to recruiting for and conducting clinical trials. However, clinical trials represent the safest and most effective way to generate scientific evidence on prospective testing, treatment and prevention strategies to combat Coronavirus.

Ancora.ai was launched in March 2020 by Intrepida, a Swiss technology company focused on AI applications for healthcare, in recognition of the critical need to support Coronavirus clinical research.

Intrepida’s CEO, Danielle Ralic, said of the milestone 1000th trial: “It is truly impressive how quickly the global clinical research community has responded to the pandemic. Ancora.ai has posted 567 COVID-19 trials that we can connect patients and healthy volunteers to, and we are updating the site on a daily basis to provide the latest information to the public as the numbers are changing so swiftly.”

Of the clinical trials announced so far for therapeutics and vaccines, 83% are for treatments already approved and on the market for other diseases. These have a history of safety data behind them and are likely to be approved faster for COVID-19 vs. other treatments in development.

Ralic commented, “Users can register for free on Ancora.ai to search for and connect to COVID-19 trials, as a patient or a healthy volunteer, and by doing this they stand to gain early access to innovative treatments and new vaccines for the virus, which is a benefit of research participation that not many people are aware of.”

About Intrepida LLC

Intrepida LLC, founded in 2017, is focused on analytics and building artificial intelligence (AI) applications for healthcare challenges. Based in Zurich, Switzerland, the company’s mission is to improve healthcare using technology. Intrepida built Ancora.ai to help connect patients with the latest innovations in medical research, while helping trial sponsors recruit as quickly and efficiently as possible, in order to reduce delays in research, as delays in research stop new treatments from reaching patients who need them. In addition to COVID-19, Ancora.ai supports oncology indications, including breast cancer, lung cancer and cervical cancer. Cofounded by three former colleagues, Intrepida’s team has a 50/50 gender balance and includes data scientists, technologists and scientists who all share deep expertise in the healthcare industry. Intrepida is a member of NVIDIA’s Inception Program, Startup with IBM, Almirall’s Digital Garden, the Barcelona Health Hub, the Future Perfect accelerator for COVID-19, and has participated in the Google for Startups Female Founders Program.

Contact Info:
Name: Emily Jordan
Email: Send Email
Organization: Intrepida
Address: Pfingstweidstrasse, 8005 Zürich, Switzerland
Phone: +49 1778405531
Website: http://www.ancora.ai

Video URL: https://www.youtube.com/channel/UCBWHw4VShOAreUcHkD77Vdw/videos

Source URL: https://marketersmedia.com/1000th-covid-19-clinical-trial-posted-today-a-milestone-signaling-the-continued-exponential-growth-in-research-efforts-against-coronavirus/88955676

Source: MarketersMedia

Release ID: 88955676

Consumption of Snack Pellets Soars as More Consumers Prefer Prepares Foods; COVID-19 Induced Limitations to Hinder Market in Immediate Future: Future Market Insights

DUBAI, UAE / ACCESSWIRE / April 30, 2020 / The global snack pellets market is on a positive growth trajectory and is poised to witness a promising CAGR of 5.5% during the forecast period (2020-2029), according to a market study by Future Market Insights (FMI).

However, the market is likely to face an adversary in the form of COVID-19. With North America – the leading regional market – being severely affected by the outbreak, the market is likely to witness a decline in consumer demand. The numerous regulatory measures in place are hindering operations and disrupting supply chains. This can negatively impact market growth in the immediate future.

"Factors predominantly fueling the growth are the rising demand for processed foods, increasing trend of healthy snacking and the growing preference for fat-free and enhanced flavor snacks," says the FMI study.

For more insights into the Market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-11220

Segmental Highlights

Gelatinized pellets segment is expected to capture a majority of market share on the back of their uniformity and thickness, which keeps them consistent during frying or toasting.

Tridimensional pellets segment is forecasted to grow at a higher CAGR as compared to gelatinized pallets during the forecast period.

Potato snack pellets segment also holds a respectable share in the global snacks pellets market owing to high consumer demand in the North American region.

Single-screw extruder technique will remain the most sought-out technique among end-users during the forecast period.

North America is anticipated to persist dominance as the leading regional market for snack pallets, backed by the ample supply of raw materials and the significant presence of a powerful food processing industry.

Europe is bestowing substantial revenue opportunities to players in the snack pellets market, and is expected to capture more than 1/3rs of the overall market share.

For information on the research approach used in the report, request methodology@ https://www.futuremarketinsights.com/askus/rep-gb-11220

Report Coverage:

Types covered: Potato-based snack pellets, rice-based snack pellets, corn-based snack pellets, multigrain snack pellets and tapioca-based snack pellets

Forms covered: Fie-face, tridimensional, laminated and gelatinized.

Techniques covered:

Regions covered: North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Explore Extensive Coverage of FMI's Food & Beverages Landscape

Custom Dry Ingredients Market– Obtain valuable insights on the custom dry ingredients market with exhaustive segmental analysis, market statistics, key influencing factors, prominent players and critical developmental strategies adopted by them for a predefined projection period.

Beverage Stabilizer Market– FMI's report on the global beverage stabilizer market offers an in-depth commentary on the market poised for prolific growth during 2017-2028. The study covers a comprehensive evaluation of key impacting forces, revenue sources, and market leaders along with instrumental market strategies.

Revivable Yeast Market– Get a deep-dive analysis on the global revivable yeast market with crucial insights on growth levers, opportunities, restraints, regulatory policies, regional market forecast and key forte of market leaders.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Report: https://www.futuremarketinsights.com/reports/snack-pellets-market
Press Release Source: https://www.futuremarketinsights.com/press-release/snack-pellets-market

SOURCE: Future Market Insights

ReleaseID: 587765

Avinger Closes $3.15 Million Equity Offering

REDWOOD CITY, CA / ACCESSWIRE / April 30, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 12,600,000 shares of its common stock at a price of $0.25 per share, for total gross proceeds of approximately $3.15 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 15% additional shares of common stock to cover over-allotments, if any. The shares were offered pursuant to a registration statement on Form S-1 previously filed with and declared effective by the Securities and Exchange Commission (SEC). A final prospectus relating to the offering was filed with the SEC and is available on the SEC's website at www.sec.gov.

Aegis Capital Corp. is acting as sole bookrunner for the offering.

A copy of the final prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th floor, New York, NY 10019, by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Safe Harbor Disclosure

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the option granted by the Company to the underwriters and other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: the effects of the COVID-19 pandemic on our operations and general economic conditions; as well as other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the SEC on March 6, 2020 and in our other filings with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Contact:

Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200

SOURCE: Avinger, Inc.

ReleaseID: 587769

BIDU INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Baidu, Inc. and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / April 30, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Baidu, Inc. ("Baidu" or "the Company") (NASDAQ:BIDU) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Baidu securities between March 16, 2019 through April 7, 2020 , both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/bidu.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Baidu's feed services were not in compliance with applicable Chinese regulatory standards; (2) the foregoing noncompliance subjected the Company to a heightened risk of regulatory enforcement, including the removal or suspension of certain of Baidu's services and products; (3) accordingly, the Company's revenues derived from online marketing services were unlikely to be sustainable; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/bidu or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Baidu you have until June 22, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 587075

SHAREHOLDER ALERT: CAN CRON DNK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / April 30, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Canaan Inc. (NASDAQ:CAN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/canaan-inc-loss-submission-form?prid=6271&wire=1
Lead Plaintiff Deadline: May 4, 2020
Class Period: publicly traded securities of Canaan, including its American Depository Shares pursuant and/or traceable to the Company's registration statement and related prospectus issued in connection with the Company's November 20, 2019 initial public offering.

Allegations against CAN include that: (1) the purported "strategic cooperation" was actually a transaction with a related party; (2) the company's financial health was worse than what was actually reported; (3) the company had recently removed numerous distributors from its website just prior to the initial public offering, many of which were small or suspicious businesses; and (4) several of the Company's largest Chinese clients in prior years were clients who were not in the Bitcoin mining industry and, thus, would likely not be repeat customers.

Cronos Group Inc. (NASDAQ:CRON)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/cronos-group-inc-loss-submission-form-2?prid=6271&wire=1
Lead Plaintiff Deadline: May 11, 2020
Class Period: May 9, 2019 to March 2, 2020

Allegations against CRON include that: (i) Cronos had engaged in significant transactions for which its revenue recognition was inappropriate; (ii) the foregoing would foreseeably necessitate reviews that would delay the Company's ability to timely file its periodic reports; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Phoenix Tree Holdings Limited (NYSE:DNK)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/phoenix-tree-holdings-limited-loss-submission-form?prid=6271&wire=1
Lead Plaintiff Deadline: June 26, 2020
Class Period: American Depositary Shares ("ADS") of Phoenix pursuant and/or traceable to prospectuses and registration statements issued in connection with the Company's January 2020 initial public offering.

According to the filed complaint, the documents Phoenix Tree issued in connection with its initial public offering ("IPO") omitted or otherwise misrepresented the nature and level of renter complaints the Company had received before and as of the IPO, as well as the demand in the Chinese residential rental market and the Company's exposure to significant adverse developments resulting from the onset of the coronavirus in China – particularly in Wuhan – at the time of the IPO. After the IPO, reports emerged indicating that Phoenix was experiencing ongoing problems due to the coronavirus, which was causing financial and other harm to tenants.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 587770